Federal grants expand opioid treatment for uninsured Americans
H.R. 9675 — Expanding Opportunities for Recovery Act of 2026 · Filed by Bill Foster (D-IL) · Introduced Jul 14, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes federal grants to states to expand access to opioid addiction treatment services, particularly medication-assisted treatment, for uninsured or underinsured individuals. States receiving grants must ensure services are evidence-based, physician-recommended, and provided only to people lacking adequate insurance coverage, with a 60-day per-person treatment limit and 5% of funds reserved for evaluation and technical assistance.
Why we flagged it
The bill's operative mechanism is a straightforward federal grant program to expand evidence-based addiction treatment access for uninsured populations. It is a public-health appropriations measure with no hidden carve-outs or industry giveaways.
What the text implies
- The 60-day per-person limit may create a cliff effect for individuals requiring longer treatment; states will need to coordinate with other funding sources or risk treatment interruption for chronic cases.
- Requirement for 'clinically appropriate' services and physician recommendation may increase administrative burden on states to verify medical necessity, potentially slowing grant deployment.
The full analysis lists 4 implications of this text.
Who stands to gain
opioid addiction treatment providers (clinics, hospitals, residential facilities); medication manufacturers (buprenorphine, methadone, naltrexone producers); state health agencies administering grants